Story perspectives

Walgreens Shares Plunge 12% Amid DOJ Lawsuit Fallout

1/22/2025

39 7

Summary

Walgreens Faces Lawsuit

Walgreens Boots Alliance shares dropped over 12% following a DOJ lawsuit alleging unlawful prescription dispensing since 2012.
The lawsuit accuses Walgreens of violating the Controlled Substances Act and the False Claims Act.
Potential civil penalties could reach $80,850 for each unlawful prescription filled.
Previously, Walgreens settled opioid-related claims for $4.8 billion and now faces increased scrutiny.
Analysts are worried about the lawsuit's financial impact on Walgreens' recovery efforts.

Summary

Walgreens Stock Declines

Walgreens Boots Alliance shares fell 12.7% amid scrutiny from institutional investors, who hold 58.59% of the stock.
Analysts' target prices vary widely, ranging from $7.00 to $16.00, indicating uncertainty about the company's future.
The company reported a quarterly EPS of $0.51, surpassing estimates, with a 7.6% year-over-year revenue increase.
Walgreens announced a quarterly dividend of $0.25, yielding around 9.15%, despite a negative payout ratio.
Recent trading experienced significant volume fluctuations, with shares ranging from $8.08 to $23.76 over the past year.

History

Historical Context

Walgreens Boots Alliance's recent 12% stock drop follows a DOJ lawsuit alleging unlawful prescription dispensing since 2012, echoing past pharmaceutical scandals like Purdue Pharma's OxyContin misbranding. Both cases reflect a broader trend of legal accountability for opioid-related practices, highlighting ongoing scrutiny of the industry's role in the opioid crisis.

1 of 3

Walgreens Faces Lawsuit

Walgreens Boots Alliance shares dropped over 12% following a DOJ lawsuit alleging unlawful prescription dispensing since 2012.
The lawsuit accuses Walgreens of violating the Controlled Substances Act and the False Claims Act.
Potential civil penalties could reach $80,850 for each unlawful prescription filled.
Previously, Walgreens settled opioid-related claims for $4.8 billion and now faces increased scrutiny.
Analysts are worried about the lawsuit's financial impact on Walgreens' recovery efforts.

1 / 3